|
Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome. |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - BostonGene |
Patents, Royalties, Other Intellectual Property - As an employee of BostonGene |
Travel, Accommodations, Expenses - BostonGene |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
Stock and Other Ownership Interests - BostonGene |
Patents, Royalties, Other Intellectual Property - I am authors in six patents owned by BostonGene; I am authors in six patents owned by BostonGene |
Travel, Accommodations, Expenses - BostonGene |
|
|
|
|
|
Consulting or Advisory Role - Eisai |
Research Funding - BostonGene |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi |
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi |
Research Funding - Janssen Oncology |
Travel, Accommodations, Expenses - Genentech/Roche |